KWALITY PHARMACEUTICALS
|
KWALITY PHARMACEUTICALS Last 5 Year Financial Ratios History
[Consolidated]
| Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 22.93 | 18.67 | 115.64 | 14.60 | 8.02 |
| CEPS(Rs) | 41.61 | 33.00 | 125.89 | 20.61 | 12.18 |
| DPS(Rs) | - | - | - | - | - |
| Book NAV/Share(Rs) | 215.31 | 192.48 | 173.81 | 58.16 | 43.57 |
| Tax Rate(%) | 24.06 | 24.61 | 25.77 | 30.01 | 24.83 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 21.59 | 24.19 | 37.63 | 11.01 | 10.19 |
| EBIT Margin(%) | 13.51 | 12.82 | 36.06 | 9.14 | 9.63 |
| Pre Tax Margin(%) | 10.12 | 10.19 | 35.42 | 8.12 | 7.84 |
| PAT Margin (%) | 7.69 | 7.68 | 26.29 | 5.68 | 5.89 |
| Cash Profit Margin (%) | 14.06 | 13.64 | 28.64 | 8.16 | 9.07 |
| Performance Ratios | |||||
| ROA(%) | 6.32 | 5.55 | 47.33 | 9.97 | 6.90 |
| ROE(%) | 11.16 | 10.15 | 99.66 | 28.21 | 20.10 |
| ROCE(%) | 13.57 | 12.27 | 97.93 | 26.35 | 18.46 |
| Asset Turnover(x) | 0.82 | 0.72 | 1.80 | 1.75 | 1.17 |
| Sales/Fixed Asset(x) | 1.63 | 1.68 | 4.34 | 3.62 | 2.69 |
| Working Capital/Sales(x) | 3.38 | 3.09 | 5.16 | 9.49 | 6.55 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.61 | 0.59 | 0.23 | 0.28 | 0.37 |
| Receivable days | 110.56 | 102.38 | 41.94 | 46.00 | 90.08 |
| Inventory Days | 97.85 | 101.54 | 28.29 | 27.71 | 44.10 |
| Payable days | 161.90 | 183.20 | 78.14 | 54.20 | 83.90 |
| Valuation Parameters | |||||
| PER(x) | 17.85 | 16.47 | 5.02 | 3.84 | 3.19 |
| PCE(x) | 9.84 | 9.32 | 4.61 | 2.72 | 2.10 |
| Price/Book(x) | 1.90 | 1.60 | 3.34 | 0.96 | 0.59 |
| Yield(%) | - | - | - | - | - |
| EV/Net Sales(x) | 1.68 | 1.60 | 1.41 | 0.36 | 0.43 |
| EV/Core EBITDA(x) | 7.59 | 6.31 | 3.67 | 3.07 | 3.36 |
| EV/EBIT(x) | 12.46 | 12.49 | 3.91 | 3.91 | 4.47 |
| EV/CE(x) | 1.61 | 1.39 | 1.89 | 0.56 | 0.45 |
| M Cap / Sales | 1.38 | 1.27 | 1.32 | 0.22 | 0.19 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 22.36 | -44.97 | 74.11 | 88.10 | -16.23 |
| Core EBITDA Growth(%) | 7.03 | -63.65 | 475.48 | 70.50 | 9.45 |
| EBIT Growth(%) | 28.92 | -80.44 | 586.87 | 78.45 | 1.71 |
| PAT Growth(%) | 22.49 | -83.93 | 705.63 | 81.40 | 8.60 |
| EPS Growth(%) | 22.83 | -83.86 | 692.23 | 82.11 | 10.13 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.44 | 0.45 | 0.30 | 0.68 | 0.77 |
| Current Ratio(x) | 1.60 | 1.65 | 1.63 | 1.35 | 1.31 |
| Quick Ratio(x) | 1.08 | 0.96 | 1.25 | 1.14 | 1.00 |
| Interest Cover(x) | 3.99 | 4.87 | 56.38 | 8.95 | 5.36 |
| Total Debt/Mcap(x) | 0.23 | 0.28 | 0.09 | 0.71 | 1.32 |
Compare Financial Ratios of peers of KWALITY PHARMACEUTICALS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| KWALITY PHARMACEUTICALS | ₹730.1 Cr | -13.7% | -32.5% | 62.1% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹407,827.0 Cr | -3.1% | -3.9% | 12.9% | Stock Analytics | |
| DIVIS LABORATORIES | ₹157,931.0 Cr | -2.9% | -0.8% | 62.5% | Stock Analytics | |
| CIPLA | ₹117,322.0 Cr | 1.1% | 0.3% | 1.4% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹101,116.0 Cr | -1.3% | -9.4% | -0.8% | Stock Analytics | |
| ZYDUS LIFESCIENCES | ₹94,752.0 Cr | -3.7% | -5.9% | 19.7% | Stock Analytics | |
KWALITY PHARMACEUTICALS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| KWALITY PHARMACEUTICALS | -13.7% |
-32.5% |
62.1% |
| SENSEX | -2.9% |
-0.1% |
6.8% |
You may also like the below Video Courses
